Across TCGA pan-cancer cohorts, LINC01312 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated LINC01312 data layer compared with 1 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LINC01312 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01312 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.
LUAD, CESC, and THCA are the cancer types where LINC01312 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.